Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults

NCT01314014 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT01314014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01314014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Amplimexon® (Imexon for Injection) for the Treatment of Previously Treated Follicular and Aggressive Lymphoma in Adults
Lead sponsor
University of Rochester
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
August 31, 2014
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt's lymphoma, diffuse large b cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma